Oxford and AstraZeneca vaccine achieved 99 percent immunity in phase 2

Modesto Morganelli
Novembre 23, 2020

AstraZeneca and Oxford University's potential COVID-19 vaccine produced a strong immune response in older adults, data published on Thursday showed, with researchers expecting to release late-stage trial results by Christmas.

Whether CoronaVac actually prevents people catching the coronavirus is now being assessed in phase 3 studies in Brazil, Indonesia and Turkey, along with the closely watched T-cell response triggered by the vaccine. "We hope that this means our vaccine will help to protect some of the most vulnerable people in society, but further research will be needed before we can be sure", she said in the release.

Late-stage, or Phase III, trials are ongoing to confirm the findings, researchers said, and to test whether the vaccine protects against infection with SARS-CoV-2 in a broad range of people, including people with underlying health conditions.

WATCH | How well will COVID-19 vaccines work in the real world?

The government is exploring the modalities of emergency authorisation and usage of anti-coronavirus vaccines pending completion of phase-three clinical trial and regular licensure.

Space to play or pause, M to mute, left and right arrows to seek, up and down arrows for volume.

The Oxford-AstraZeneca COVID-19 vaccine candidate had been among the front-runners in global efforts to develop shots to protect against coronavirus infection.

Competition has intensified among pharmaceutical companies racing to develop a Covid-19 shot, with two vaccines - one by U.S. company Pfizer and its German partner BioNTech, and another by United States firm Moderna - publishing large-scale trial data this month that showed their jabs were around 95 percent effective against Covid-19.

"We're not in a rush. We and it's not a competition with the other developers", Oxford's Professor Pollard said, adding that AstraZeneca would release headline efficacy data before it was published in an academic journal.

Both Pfizer and Moderna's vaccines use messenger RNA (mRNA), boosting the body's immune response against the virus.

The Phase II trial reported in The Lancet involved a total of 560 healthy volunteers, with 160 aged 18-55 years, 160 aged 56-69 years, and 240 aged 70 or over.

Volunteers got two doses of the vaccine or a placebo, and no serious side effects related to the vaccine were reported, the researchers said.

AstraZeneca has signed several supply and manufacturing deals with companies and governments around the world.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE